All > New York > Washington

ICP-723 for Advanced Solid Tumors

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advanced Solid TumorsICP-723 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new drug for people with cancer who have no other options. They will test how well the drug works and if it has any side effects.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
BTX-1188
1
AN4005 dose level 2
1
Gamitrinib

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: through study completion, an average of 1.5 years.

Year 4
Apparent clearance (CL/F)
Apparent volume of distribution (Vz/F)
Area under the plasma concentration-time curve (AUC0-∞ and AUC0-t)
Disease control rate (DCR) determined using RECIST 1.1 criteria.
Half-life (t1/2)
Objective response rate (ORR) determined using RECIST 1.1 criteria.
Peak concentration (Cmax)
Time to reach peak concentration (Tmax)
Year 5
Incidence and severity of dose-limiting toxicity (DLT), adverse events (AEs), and serious adverse events (SAEs). Frequency of dose interruptions, reductions and intensity

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
BTX-1188
1
AN4005 dose level 2
1
Gamitrinib

Trial Design

1 Treatment Group

ICP-723
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: ICP-723 · No Placebo Group · Phase 1

ICP-723
Drug
Experimental Group · 1 Intervention: ICP-723 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion, an average of 1.5 years.

Who is running the clinical trial?

InnoCare Pharma Inc.Lead Sponsor
Jun ZhangPrincipal InvestigatorUniversity of Kansas Medical / Cancer Centers
4 Previous Clinical Trials
5,529 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have a primary CNS tumor or CNS metastases.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top